Table 5.
Cost-effectiveness analysis of different combinations of tumor markers at the current cost and with a 10% decrease in cost.
| Group | Cost (C)/¥ | Effectiveness (E)/% | C/E | ΔC/ΔE |
|---|---|---|---|---|
| SCCA + NSE | 177 (159.3) | 56.82 | 3.12 (2.80) | 0.00 (0.00) |
| SCCA + CEA | 177 (159.3) | 60.61 | 2.92 (2.63) | 0.00 (0.00) |
| NSE + CEA | 200 (180) | 67.42 | 2.97 (2.67) | 2.17 (1.95) |
| NSE + CYFRA21-1 | 200 (180) | 64.39 | 3.11 (2.80) | 3.04 (2.73) |
| CEA + CYFRA21-1 | 200 (180) | 64.39 | 3.11 (2.80) | 3.04 (2.73) |
| SCCA + NSE + CEA | 277 (249.3) | 70.45 | 3.93 (3.54) | 7.34 (6.60) |
| SCCA + NSE + CYFRA21-1 | 277 (249.3) | 65.15 | 4.25 (3.83) | 12.00 (10.80) |
| SCCA + CEA + CYFRA21-1 | 277 (249.3) | 70.45 | 3.93 (3.54) | 7.34 (6.60) |
| NSE + CEA + CYFRA21-1 | 300 (270) | 75.76 | 3.96 (3.56) | 6.49 (5.84) |
| SCCA + NSE + CEA + CYFRA21-1 | 377 (339.3) | 78.03 | 4.83 (4.35) | 9.43 (8.49) |